SCHEMBL21618335

SCHEMBL21618335

[CH2]C12CC(NC(=O)COc3ccc(Cl)cn3)(C1)C2

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 11/20 0.56
▸ RAB9A P51151 5/20 0.44
▸ NPC1 O15118 4/20 0.44
▸ TSHR P16473 2/20 0.44
▸ TP53 P04637 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ MAPT P10636 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23149156 0.86 ATF4 (0.78) ATF4RAB9ANPC1TSHRMAPT
SCHEMBL21618322 0.81 ATF4 (0.83) ATF4RAB9ANPC1TSHRL3MBTL1
SCHEMBL22956487 0.79 ATF4 (0.50) ATF4RAB9ANPC1TSHRTP53
SCHEMBL23149185 0.79 ATF4 (0.62) ATF4RAB9ANPC1TSHRSMN1; SMN2
SCHEMBL20973815 0.79 ATF4 (0.64) ATF4
SCHEMBL30026071 0.79 ATF4 (0.64) ATF4
SCHEMBL23183015 0.76 ATF4 (0.44) ATF4L3MBTL1
SCHEMBL23182747 0.76 ATF4 (0.46) ATF4RAB9ANPC1TSHR
SCHEMBL21618352 0.74 ATF4 (0.80) ATF4RAB9ANPC1TSHRL3MBTL1
SCHEMBL21618341 0.73 ATF4 (0.60) ATF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253528-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US claimed
EP-3820843-A1 CHEMICAL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-05-19 — — EP claimed
WO-2020012339-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-01-16 — — WO claimed
US-20210253528-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
EP-3820843-A1 CHEMICAL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-05-19 — — EP disclosed
WO-2020012339-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253528-A1 CHEMICAL COMPOUNDS ATF4, EIF2AK4, ATF1 ATF4 1/4885RAB9A 2271/4885NPC1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback